Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

EDSA
Edesa Biotech, Inc. Common Shares
stock NASDAQ

At Close
Apr 2, 2026 3:59:59 PM EDT
6.17USD+11.171%(+0.62)418,063
0.00Bid   0.00Ask   0.00Spread
Pre-market
Apr 2, 2026 9:25:30 AM EDT
5.35USD-3.604%(-0.20)1,834
After-hours
Apr 2, 2026 4:41:30 PM EDT
6.02USD-2.431%(-0.15)1,079
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 13, 2022
11:47AM EST  Edesa Biotech Receives Canadian Approval To Test COVID-19 Drug As Rescue Therapy   Benzinga
Dec 28, 2021
06:29PM EST  Recap: Edesa Biotech Q4 Earnings   Benzinga
04:25PM EST  Edesa Biotech Q4 EPS $(1.10)   Benzinga
Dec 20, 2021
11:58AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2021   Benzinga
06:10AM EST  HC Wainwright & Co. Initiates Coverage On Edesa Biotech with Buy Rating, Announces Price Target of $16   Benzinga
Dec 1, 2021
08:07AM EST  Edesa Biotech Says Has Completed Enrollment In Mover Than 75% Of Patients Planned For Cohort Of Phase 2b Study Evaluating EB01   Benzinga
Nov 4, 2021
08:18AM EDT  Edesa Biotech Extends COVID-19 Clinical Study To Poland   Benzinga
Oct 21, 2021
02:08PM EDT  UPDATE: Zacks Small Cap Research Has $20 Price Target On Edesa Biotech   Benzinga
02:08PM EDT  Zacks Small Cap Research Issues Note On Edesa Biotech 'Additional Favorable Mortality Reductions Identified in COVID-19 Trial'   Benzinga
Oct 19, 2021
09:32AM EDT  Why Edesa Biotech Shares Are Trading Higher Today   Benzinga
08:01AM EDT  Edesa Biotech Announces Additional Results From Phase 2 Part Of Ongoing Phase 2/3 Study Of EB05 In COVID-19; Says 'Mortality reductions demonstrated across multiple patient groups'   Benzinga
Sep 25, 2021
11:21AM EDT  EDSA: EB05 Reduces Risk of COVID Death by 68.5% in Critically Ill Patients   Benzinga
Sep 21, 2021
02:33PM EDT  Mid-Afternoon Market Update: Dow Edges Lower; Helbiz Shares Spike Higher   Benzinga
12:13PM EDT  Mid-Day Market Update: Gold Rises 1%; Verrica Pharmaceuticals Shares Slide   Benzinga
11:14AM EDT  Mid-Morning Market Update: Markets Gain; AutoZone Earnings Beat Views   Benzinga
08:51AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Sept. 21, 2021: HLBZ, XPEV, TOST, IDEX, EDSA   Benzinga
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 20, 2021
03:13PM EDT  UPDATE: Zacks Small Cap Research Raises Price Target On Edesa Bio From $16 As Of Sept. 1 To $20   Benzinga
03:12PM EDT  Zacks Small Cap Research Issues Report On Edesa Biotech 'EB05 Reduces Risk of COVID Death by 68.5% in Critically Ill Patients,' Highlights $20 Price Target   Benzinga
02:43PM EDT  Why Edesa Biotech Shares Are Soaring Today   Benzinga
02:33PM EDT  Mid-Afternoon Market Update: Dow Tumbles 2.5%; BeyondSpring Shares Plunge   Benzinga
12:09PM EDT  Mid-Day Market Update: Crude Oil Down 2%; Synlogic Shares Spike Higher   Benzinga
10:46AM EDT  Mid-Morning Market Update: Markets Open Lower; Brooks Automation Divests Semiconductor Business For $3B   Benzinga
08:05AM EDT  Edesa Biotech Announces Phase 2 Data Of Its Monoclonal Antibody In Hospitalized COVID-19 Patients; Critically Ill Patients Demonstrated A 68.5% Reduction In The Risk Of Dying When Treated With EB05 Over Standard Of Care   Benzinga
Sep 6, 2021
11:01AM EDT  EDSA: Awaiting End of Phase 2 Analysis of Phase 2/3 Study of EB05 in COVID19   Benzinga
Aug 26, 2021
07:33AM EDT  Edesa Biotech Says As Of Aug. 25, Over 525 Subjects Have Been Enrolled In EB05 Study   Benzinga
Aug 13, 2021
07:55AM EDT  Edesa Biotech Q3 EPS $(0.36) Down From $(0.20) YoY   Benzinga
Aug 5, 2021
02:00AM EDT  iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, today announces the appointment of Sean A. MacDonald to the newly-created position of Chief Business Officer. MacDonald also becomes a member of iOncturas Executive Team.   GlobeNewswire Inc
Jun 18, 2021
07:47AM EDT  Edesa Biotech Announces An Independent Data And Safety Monitoring Board Has Completed Interim Review Of Co.'s COVID-19 Candidate And Recommended Study Continue As Planned   Benzinga
Jun 4, 2021
11:11AM EDT  EDSA: Positive Interim Efficacy Analysis for EB01 Phase 2b Trial in Allergic Contact Dermatitis   Benzinga
10:55AM EDT  Zacks Small Cap Research Tweets '$EDSA: @EdesaBiotech - Positive Interim Efficacy Analysis For EB01 Phase 2b Trial In Allergic Contact Dermatitis - https://bit.ly/3z1uGqd by @DavidBautz'   Benzinga
Jun 3, 2021
08:47AM EDT  Edesa Biotech's EB01 Shows Encouraging Interim Results In Dermatitis Trial   Benzinga
07:38AM EDT  Edesa Biotech The Company's Drug Candidate EB01 Has Met A Key Interim Study Parameter   Benzinga
May 14, 2021
08:02AM EDT  Edesa Biotech Q2 EPS $(0.19) Down From $(0.17) YoY   Benzinga
Mar 26, 2021
11:14AM EDT  Insider Buys Edesa Biotech Inc.'s Stock   Benzinga
Mar 22, 2021
08:10AM EDT  Edesa Biotech 8-K Shows Co.'s Research Subsidiary Entered Exclusive License Deal With Dr. Paul Yedgar For Added Global Rights To A Pharmacy Product That forms Basis Of Co.'s ED01, EB02 Drug Candidates   Benzinga
Mar 15, 2021
08:22AM EDT  Edesa Biotech Completes Enrollment Of More Than 50% Of Patients I Phase 2 Portion Of Phase 2/Phase 3 Study Of EB05 In COVID-19 Patients   Benzinga
Mar 9, 2021
09:16AM EST  Edesa Biotech Completes Enrollment In First Cohort Of Phase 2b Study Evaluating EB01 In Allergic Contact Dermatitis   Benzinga
Feb 26, 2021
08:17AM EST  The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida   Benzinga
05:32AM EST  Edesa Biotech Increased Previously Announced Bought Deal Offering of Common Shares to $10M; Priced 1.56M Shares @$6.40/Share   Benzinga
Feb 25, 2021
05:42PM EST  Edesa Biotech Announces $3.5M Bought Deal Offering Of 546,875 Shares At $6.40/Share   Benzinga
Feb 16, 2021
07:37AM EST  Edesa Biotech Q1 EPS $(0.26) Down From $(0.15) YoY   Benzinga
Feb 2, 2021
12:18PM EST  Edesa Biotech Shares Move Higher; Co Says Granted C$14M For COVID-19 Study   Benzinga
Jan 26, 2021
02:30PM EST  Mid-Afternoon Market Update: Dow Rises 40 Points; Repro Med Systems Shares Plunge   Benzinga
12:45PM EST  Mid-Day Market Update: Crude Oil Down 0.5%; Vir Biotechnology Shares Spike Higher   Benzinga
10:12AM EST  Mid-Morning Market Update: Markets Edge Higher; Verizon Tops Q4 Views   Benzinga
09:52AM EST  Shares of Edesa Biotech, Inc. (EDSA) are currently surging over 35% after the company received approval to study its investigational drug as treatment of Acute Respiratory Distress Syndrome.   RTTNews
07:34AM EST  Edesa Biotech Receives FDA And Health Canada Approval To Add Sub-Study To Its Phase 2/Phase 3 Of EB05; Sub-Study To Evaluate EB05 As Potential Rescue Therapy For Critically Severe COVID--19 Vases   Benzinga
Jan 20, 2021
10:49AM EST  Shares of Edesa Biotech, Inc. (EDSA) are rising more than 20% Wednesday morning at $6.11.   RTTNews
07:47AM EST  Edesa Biotech To Join Panel Discussion At Government COVID-19 Event   Benzinga
Jan 11, 2021
07:33AM EST  Edesa Biotech Expands COVID-19 Clinical Study To Colombia   Benzinga
Dec 10, 2020
11:15AM EST  Watching Edesa Biotech Shares; Hearing ZACKS Sets $15 Price Target   Benzinga
Dec 7, 2020
07:52AM EST  Edesa Biotech Reports YF 2020 EPS $(0.74); Revs. $328K   Benzinga
Nov 30, 2020
07:32AM EST  Edesa Biotech Enrolls First Patient in COVID-19 Study   Benzinga
Nov 3, 2020
07:27AM EST  Edesa Biotech Achieves Enrollment Milestone In Dermatitis Study   Benzinga
Oct 19, 2020
11:05AM EDT  Edesa Biotech shares are trading higher after the company announced it has received clearance from the FDA to begin the Phase 2 portion of its Phase 2/3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients. UPDATE: Shares have since reversed, now lower.   Benzinga
10:05AM EDT  Shares of Edesa Biotech, Inc. (EDSA), a Canada-based clinical-stage biopharmaceutical company, are rising more than 14 percent or $1.08 in Monday's morning trade at $8.78.   RTTNews
07:35AM EDT  Edesa Biotech Receives Approval To Initiate COVID-19 Study In US   Benzinga
Sep 18, 2020
08:14AM EDT  Edesa Biotech Amended 13D Filing From CEO Pardeep Nijhawan Shows 34.4% Stake In Co.   Benzinga
Aug 12, 2020
07:49AM EDT  Edesa Biotech Q3 EPS $(0.20) Up From $(0.30) YoY, Sales $110K   Benzinga
Jul 30, 2020
02:32PM EDT  Mid-Afternoon Market Update: Nasdaq Turns Higher; Kraton Shares Plummet   Benzinga
12:17PM EDT  Mid-Day Market Update: Crude Oil Down 3%; At Home Group Shares Spike Higher   Benzinga
10:47AM EDT  Shares of clinical-stage biopharmaceutical company Edesa Biotech, Inc. (EDSA) are surging more than 150% Thursday morning after the company said it has filed an investigational new drug (IND) application with the FDA to start phase II/III study of its drug candidate, EB05 in hospitalized Covid-19 patients.   RTTNews
10:15AM EDT  Mid-Morning Market Update: Markets Open Lower; Procter & Gamble Tops Q4 Views   Benzinga
07:48AM EDT  Edesa Biotech Files IND Application For Phase 2/3 Coronavirus Study   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC